Tranexamic Acid in Gastrointestinal Bleeding

Evidence Against TXA Use

• The American College of Gastroenterology recommends against using high-dose IV TXA for gastrointestinal bleeding due to lack of benefit and increased thrombotic risk 1
• The use of TXA in gastrointestinal bleeding increases the risk of venous thromboembolism, including deep vein thrombosis and pulmonary embolism, with a relative risk of 2.01 and 1.78, respectively 2

Current Guideline Recommendations

• The British Society of Gastroenterology suggests that TXA use in acute lower GI bleeding should be confined to clinical trials only, pending results of larger studies 2, 1
• The European Association for the Study of the Liver strongly recommends against using TXA in patients with cirrhosis and active variceal bleeding 2, 1

What to Do Instead

• Resuscitation with a restrictive transfusion strategy, targeting a hemoglobin level of 7-9 g/dL in upper GI bleeding, is recommended 1
• Early endoscopic intervention for diagnosis and treatment is recommended 2
• High-dose proton pump inhibitor therapy, consisting of 80 mg omeprazole stat followed by 8 mg/hour infusion for 72 hours, is recommended following successful endoscopic therapy for ulcer bleeding 3
• For variceal bleeding, vasoactive drugs, antibiotics, and endoscopic band ligation are recommended, rather than TXA 1

Important Caveats

• TXA may be considered for mild GI bleeding in patients with Hereditary Hemorrhagic Telangiectasia (HHT), based on low potential for harm in this specific population 1

Tranexamic Acid in Gastrointestinal Bleeding

Guideline Recommendations

• The American College of Gastroenterology explicitly recommends against using high-dose IV TXA for gastrointestinal bleeding due to lack of benefit and increased thrombotic risk, although the specific citation is not provided, a similar recommendation is made by other societies 4
• For patients with Hereditary Hemorrhagic Telangiectasia (HHT), oral tranexamic acid may be considered only for mild GI bleeding, with a low potential for harm in this specific population, based on evidence from Blood 2021 4

Treatment of GI Bleeding in HHT Patients

• For HHT patients with mild GI bleeding, oral TXA 500 mg twice daily, gradually increasing to 1000 mg four times daily, may be considered, based on evidence from Blood 2021 4

Tranexamic Acid in Gastrointestinal Bleeding

Introduction to TXA Failure in GI Bleeding

• The Journal of Hepatology reports that high-dose IV tranexamic acid provides no reduction in rebleeding rates in patients with gastrointestinal bleeding, with nearly 50% of the HALT-IT cohort having suspected variceal bleeding 5
• The pathophysiology of GI bleeding differs fundamentally from traumatic hemorrhage, making trauma or surgical bleeding data inapplicable to GI bleeding 5
• In cirrhosis, standard coagulation tests do not reflect true hemostatic capacity, and transfusion of blood products may paradoxically increase portal pressure and worsen bleeding 5

Specific Considerations for Bleeding Management

• Portal pressure-lowering measures are recommended for non-variceal portal hypertensive bleeding 5

Tranexamic Acid in Gastrointestinal Bleeding

Special Populations Requiring Extra Caution

• For cirrhotic patients undergoing invasive procedures, routine TXA use is discouraged due to the risk of disrupting the fragile balance of the fibrinolytic system and increasing venous thromboembolism risk 6
• In patients with chronic or acute renal failure, reduced doses of TXA are indicated, but given the lack of efficacy in lower GI bleeding, even dose-adjusted TXA should not be used 6
• Transfusion of blood products can paradoxically increase portal pressure by increasing blood volume, potentially worsening bleeding in cirrhotic patients 6
• The European Association for the Study of the Liver provides a strong recommendation against TXA use in patients with cirrhosis and active variceal bleeding, and TXA should be avoided in these patients 6

Evidence-Based Management Algorithm

• Optimize hemoglobin by treating iron, folic acid, vitamin B6, and B12 deficiencies in patients with lower GI bleeding 6

Tranexamic Acid in Gastrointestinal Bleeding

Introduction to Tranexamic Acid Use

• The CRASH-2 trial demonstrated a mortality benefit with tranexamic acid in trauma, but this does not apply to gastrointestinal bleeding pathophysiology, as shown in the Critical Care journal 7

Specific Populations and Evidence-Based Management

• No specific facts with citations are available in the provided article, except for the mention of the CRASH-2 trial in the context of trauma, not gastrointestinal bleeding 7

Tranexamic Acid in Specific Gastrointestinal Bleeding Contexts

Hereditary Hemorrhagic Telangiectasia (HHT)

• Oral tranexamic acid can be considered for patients with HHT who have mild gastrointestinal bleeding and achieve hemoglobin targets with oral iron supplementation; the recommendation is based on limited evidence and a low potential for harm. 8
• A typical dosing regimen starts with 500 mg orally twice daily and may be titrated up to 1 g four times daily or 1.5 g three times daily, depending on tolerance and response. 8
• Recent thrombotic events are an absolute contraindication to tranexamic acid; relative contraindications include atrial fibrillation or known thrombophilia. 8

Extrapolation of Trauma Trial Data to Gastrointestinal Bleeding

• Although tranexamic acid reduces mortality in trauma patients (as demonstrated in the CRASH‑2 trial), this benefit does not translate to acute gastrointestinal bleeding because the underlying pathophysiology differs markedly; therefore, trauma data should not be applied to GI bleeding management. 9

Guidelines and Evidence on Tranexamic Acid Use in Gastrointestinal Bleeding

Evidence from Prior Meta‑analyses

• Older meta‑analyses published before 2021 reported a mortality benefit of tranexamic acid in gastrointestinal bleeding, but these studies included small, historic trials conducted prior to modern endoscopic therapy and high‑dose proton‑pump inhibitor use, rendering their conclusions outdated for current practice. Strength of evidence: low (historical, high risk of bias) 10

Guideline Recommendations

• The British Society of Gastroenterology advises that tranexamic acid should be limited to use within clinical trials for gastrointestinal bleeding until larger, contemporary studies provide definitive safety and efficacy data. Strength of recommendation: conditional (based on limited contemporary evidence) 10

Required Hospital Infrastructure for Acute GI Bleeding Management

• Institutions managing acute gastrointestinal bleeding should maintain 24‑hour, on‑site access to colonoscopy and endoscopic therapeutic capabilities to ensure timely diagnosis and treatment. Strength of recommendation: strong (based on consensus standards) 10

• Facilities should also provide 24‑hour, on‑site or formally coordinated access to interventional radiology services to allow rapid embolization or other minimally invasive interventions when endoscopic control fails. Strength of recommendation: strong (based on consensus standards) 10

Tranexamic Acid in Lower Gastrointestinal Bleeding

Primary Guideline Recommendations

• The British Society of Gastroenterology recommends that tranexamic acid use in acute lower GI bleeding should be limited to clinical trials, pending results of larger contemporary studies, due to lack of efficacy data specific to lower GI bleeding and increased thrombotic risk 11
• The British Society of Gastroenterology explicitly states that tranexamic acid is not recommended for lower gastrointestinal bleeding and should be confined to clinical trials only, based on evidence from upper GI bleeding studies conducted before modern endoscopic therapy and high-dose proton pump inhibitors became standard 11

Direct Evidence from Lower GI Bleeding Studies and Management

• Early colonoscopy with 7-day-per-week on-site access and endoscopic therapeutic capabilities is recommended for lower GI bleeding management, as part of standard resuscitation and intervention 11
• The British Society of Gastroenterology recommends 24/7 interventional radiology access, either on-site or via formalized referral pathway, for embolization when endoscopic control fails in lower GI bleeding management 11

Tranexamic Acid in Non‑Variceal Upper Gastrointestinal Bleeding: Evidence‑Based Recommendations

Applicability of Trauma Trial Data

• The findings of the CRASH‑2 trauma trial on tranexamic acid cannot be extrapolated to acute non‑variceal upper gastrointestinal bleeding because the underlying pathophysiology of GI bleeding differs fundamentally from traumatic hemorrhage, rendering the trauma data inapplicable to this clinical scenario. 12

Post‑Endoscopic Pharmacologic Management

• Following successful endoscopic hemostasis for non‑variceal upper GI bleeding, high‑dose proton‑pump inhibitor therapy (80 mg intravenous bolus of omeprazole followed by a continuous infusion of 8 mg/hour for 72 hours) is recommended to minimize re‑bleeding risk. This recommendation is based on evidence from randomized studies published in Gut (2002). 13

Reassessment of Historical Meta‑Analyses

• Older meta‑analyses that reported a mortality benefit of tranexamic acid in gastrointestinal bleeding are considered outdated; they relied on small, pre‑endoscopic‑era trials conducted before modern high‑dose PPI use became standard. Current guidelines therefore advise against routine use of any tranexamic acid formulation for GI bleeding outside of clinical trials. This conclusion is drawn from the same Gut (2002) publications. 14